GLAXOSMITHKLINE PLC Form 6-K April 13, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 13 April 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

1		
	Details of PDMR/person closely associate	
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction
a)	Name	GlaxoSmithKline plc
	LEI	5493000HZTVUYLO1D793
0)	Details of the transaction(s): section to b	
3	instrument; (ii) each type of transaction;	
5.	place where transaction(s) has been cond	
	place where transaction(s) has been cone	Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	ISIN: GB0009252882
		ISIN. OB0009252882
		Acquisition of Ordinary
		Acquisition of Ordinary
		Shares following the
1 \		re-investment of dividends
b)	Nature of the transaction	paid to shareholders on 12
		April 2018, on shares held
		through the Company's Share
		Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s)
0)	Thee(3) and volume(3)	£14.4089 20
		n/a (single transaction)
	A garageted information	
d)	Aggregated information Aggregated volume Price	
	Aggregated volume Price	
`	Date of the transaction	2010 04 12
e)		2018-04-12
	Place of the transaction	London Stock Exchange
f)		(XLON)
		x = ·/

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status

	Edgar i mig	
		President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction
a)	Name	GlaxoSmithKline plc
	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction;	
	place where transaction(s) has been cond	
		Ordinary shares of 25 pence
a)	Description of the financial instrument	each ('Ordinary Shares') ISIN: GB0009252882
,	Nature of the transaction Price(s) and volume(s)	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. Price(s) Volume(s)
C)	Free(s) and volume(s)	£14.4089 77
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange (XLON)
1		
1. a)	Details of PDMR/person closely associat Name	ted with them ('PCA') Mr S Dingemans
	Position/status	Chief Financial Officer
c)	Initial notification/	Initial notification
C)	amendment	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	
	Name	GlaxoSmithKline plc
D)	LEI Details of the transaction(s): section to b	5493000HZTVUYLO1D793 e repeated for (i) each type of
3.	instrument; (ii) each type of transaction;	
	place where transaction(s) has been cond	
		Ordinary shares of 25 pence

a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s)Volume(s)£14.408927n/a (single transaction)
Aggregated informationAggregated volume Price	
	2010 04 12

e)	Date of the transaction	2018-04-12
Ð	Place of the transaction	London Stock Exchange
1)		(XLON)

1.	. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr N Hirons	
b) I	Position/status	SVP, Global Ethics &	
		Compliance	
c)	Initial notification/	Initial notification	
•)	amendment		
2.	Details of the issuer, emission allowance	market participant, auction	
	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of		
3.	. instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been cond		
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
	1 I	ISIN: GB0009252882	
		A consisting of Ordinary	
		Acquisition of Ordinary	
		Shares following the re-investment of dividends	
b)	Notice of the transaction		
0)	Nature of the transaction	paid to shareholders on 12	
		April 2018, on shares held	
		through the Company's Share Reward Plan.	
		Price(s) Volume(s)	
c)	Price(s) and volume(s)	$\pounds 14.4089$ 11	
d)	Aggregated information	n/a (single transaction)	
u)	Aggregated volume Price	in a (single transaction)	
	155105alou volume i nee		

2018-04-12

Place of the transaction London Stock Exchange f) (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D S Redfern b) Position/status Chief Strategy Officer Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2 platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £14.4089 87 n/a (single transaction) Aggregated information d) Aggregated volume Price Date of the transaction 2018-04-12 e) Place of the transaction London Stock Exchange f) (XLON)

Date of the transaction

e)

- Details of PDMR/person closely associated with them ('PCA')
 a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/ amendment Initial notification
- 2.

Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor

	platform, auctioneer of auction monitor		
a)	Name	GlaxoSmith	Kline plc
b)	LEI	5493000HZ	TVUYLO1D793
	Details of the transaction(s): section to b	e repeated for	(i) each type of
3.	instrument; (ii) each type of transaction;	be of transaction; (iii) each date; and (iv) each	
	place where transaction(s) has been cond	lucted	
		Ordinary sha	ares of 25 pence
a)	Description of the financial instrument	each ('Ordina	ary Shares')
<i>a)</i>	Description of the finaletal instrument	ISIN: GB00	09252882
		Acquisition	of Ordinary
		Shares follow	wing the
		re-investmer	nt of dividends
b)	Nature of the transaction	paid to share	cholders on 12
		•	on shares held
		U	Company's Share
		Reward Plan	1.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
•)		£14.4089	
		n/a (single tr	ansaction)
	A garageted information		

- Aggregated information d) Aggregated volume Price
- Date of the transaction 2018-04-12 e)
- Place of the transaction f)

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA') Mom MET Miel - \

a)	Name	Mr L Miels
b)	Position/status	President, Global Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence

a) Description of the financial instrument

each ('Ordinary Shares') ISIN: GB0009252882

		Acquisition of Ordinary
		Shares following the
	Nature of the transaction	re-investment of dividends
b) Nature of the transaction		paid to shareholders on 12
	April 2018, on shares held	
		through the Company's Share
		Reward Plan.
	Price(s) and volume(s)	Price(s) Volume(s)
0)		£14.4089 1
		n/a (single transaction)

d) Aggregated information Aggregated volume Price

e) Date of the transaction

f) Place of the transaction

2018-04-12 London Stock Exchange

(XLON)

a)	Details of PDMR/person closely associat Name Position/status	ted with them ('PCA') Mr P C Thomson President, Global Affairs
c) 2.	Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £14.4089 48
d)	Aggregated information Aggregated volume Price	n/a (single transaction)

e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of PDIVIR/person closely associa	ted with them (PCA)	
a)	Name	Mrs V A Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of		
3.	. instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been conc	lucted	
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
<i>a)</i>	Description of the financial instrument	ISIN: GB0009252882	
		Acquisition of Ordinary	
		Shares following the	
		re-investment of dividends	
b)	Nature of the transaction	paid to shareholders on 12	
		April 2018, on shares held	
		through the Company's Share	
		Reward Plan.	
()	Price(s) and volume(s)	Price(s) Volume(s)	
c)	Price(s) and volume(s)	£14.4089 62	
		n/a (single transaction)	

d) Aggregated information Aggregated volume Price

e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 13, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc